Biogen Reports $222M R&D Charge Impact on Q4 2025 Earnings
Biogen discloses $222 million charge for research partnerships and licensing agreements, reducing Q4 2025 earnings by $1.26 per share in SEC filing.
/ 4 items
#BIIB↓
HSBC Cuts Biogen Rating as MS Business Weakens
HSBC downgraded Biogen to Reduce, citing weakness in its multiple sclerosis business, margin pressure, and limited near-term earnings growth.
Novo Nordisk Stock Plunges 10% as Ozempic Fails Alzheimer's Trial
Novo Nordisk shares tumbled 10% after Ozempic failed to slow Alzheimer's progression in clinical trials, marking another setback for the struggling Danish drugmaker against rival Eli Lilly.
Leqembi IQLIK: At-Home Alzheimer's Treatment Brings New Hope
The US approved Leqembi IQLIK, an at-home self-injected Alzheimer's drug by Eisai & Biogen, for patients completing 18 months of IV infusions. Costing $19,500/year, it aims to boost access, convenience, and sales, despite concerns over side effects like brain swelling and bleeding.